

Aisha Ahmed M.D
Cell: (306) 450-2292
Email:draisha_80@yahoo.com

Academic Appointments

- Clinical Assistant Professor 6/2014 - Present
Department of Medicine
University of Saskatchewan. Canada

Current Position

- Medical Oncologist 6/2014 - Present
Allan Blair cancer Center, Regina, Saskatchewan, Canada
- Associate Medical Staff, Department of Cancer Services 6 / 2014 - present
Regina-Qu'Appelle Health Region

Certifications

- ABIM Certified in
✓ Internal Medicine 2011- 2021
✓ Medical Oncology 2014 - 2024
- ECFMG Certified

Medical Education & Postgraduate Training

Fellowship in Hematology & Medical Oncology Jun 2013

- Michigan State University
Breslin Cancer Center
McLaren / Sparrow Hospital, Lansing MI

Internship & Residency in Internal Medicine Jul 2008 - Jun 2011

- University of Nevada School of Medicine,
University Medical Center, Las Vegas, NV.

MD Mar 1999 – Feb 2004

- University of Karachi
Karachi Medical and Dental College, Pakistan.
-

Work Experience

**Medical Oncologist , Allan Blair Cancer Center/ Pasqua Hospital
Saskatchewan Cancer Agency
Regina, Saskatchewan**

06/2014 - current

- Extensive experience in clinical practice of Medical Oncology including both malignant hematology and solid tumors in both inpatient and outpatient settings
- Participation in clinical trials conducted by National Cancer Institute of Canada Clinical Trial Group (NCIC CTG), Alliance , Astellas, Astra Zeneca , Celgene, ROCHE in various different sites including Hematological malignancies, Breast, Gastrointestinal, Lung, Sarcoma.
- Actively involvement in monthly Clinical trial feasibility meetings
- Active participation in weekly multispecialty tumor boards including Surgical Oncology tumor rounds, Lymphoma rounds, Lung rounds, ASCO rounds
- Actively involved in developing provincial clinical practice guidelines (for Saskatchewan) for both Solid tumors and Hematological malignancies

Clinical Research Experience

Principal Investigator

- A Phase III Trial of 6 versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo For Patients With Resected Stage III Colon Cancer
- A Randomized Controlled Trial (CHALLENGE); A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with High Risk Stage II or Stage III Colon Cancer.
- A Phase III, Double-Blind, Randomized, Placebo Controlled Study (SELECT-1) to Assess the efficacy and safety of selumetinib in Combination with Docetaxel, in Patients receiveing second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic NSCLC
- Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC). (MYSTIC)
- Lung Cancer Molecular Insights Non-Interventional Study (LUMINIST)
- NCIC CTG IND.211 ; A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy

Sub - Investigator

- NCIC CTG CLC.2 (Alliance A041202) - A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (≥ 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

- NCIC CTG ALC.3 (SWOG 1203) - A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
- ATLANTIC: A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
- PACIFIC: A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
- Astra Zeneca D1532C00079 (SELECT-1) Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)
- Astellas (9785-CL-1121) A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+), Estrogen Receptor Negative (ER-)/Progesterone Receptor Negative (PgR-) Metastatic or Locally Advanced Breast Cancer
- ALLIANCE A011202: A Randomized phase III trial Evaluating the role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-T3, N1) who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy.
- NCIC CTG BL.12 . A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing on or after a Platinum.
- NCIC CTG BR.31: A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer Containing Regimen.
- CTG NCIC CEC.1: A Phase III trial of Radiotherapy with and without concurrent and adjuvant Temozolomide chemotherapy for 1p/19q non-deleted anaplastic gliomas (CATNON Trial)
- NCIC CTG CRC.7 (Alliance N1048) -- A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
- NCIC CTG GA.1 (TROG 0808) TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG).
- NCIC CTG NEC.3 (A 021202) : An Alliance-led trial entitled Prospective Randomized Phase II Trial of Pazopanib (NSC# 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumours.

- NCIC CTG IND.210 - A Randomized Phase II Study of Reolysin in Combination with FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients with Metastatic Colorectal Cancer
- NCIC CTG LYC.1 (ECOG E1411) -- Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma
- NCIC CTG MAC.15 (SWOG S1007) -- A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less, was centrally activated October 5, 2011.
- BERENICE A Multicenter, Multinational, Phase II Study to Evaluate Pertuzumab in Combination With Trastuzumab and Standard Neoadjuvant Anthracycline-based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer
- PUMA-NER-1301 (NALA)A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
- Celgene ABI-007-MBC-001 (tenacity): Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (tnAcity)

Course /Workshop Attended

- 2015 New Investigator Clinical Trials Course (NICTC) by NCIC Clinical Trials Group.
- The major goal of this to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment.
- Accredited for Maintenance of Competence (MOCOMP) credits with the Royal College of Physicians and Surgeons of Canada.

Publications

Review Article

- **Ahmed A**, Goodman Oscar. *The Relevance of BRCA Genetics to Prostate Cancer Pathogenesis and Treatment*. Clinical Advances in Hematology & Oncology. 2011;10:748-755

Basic Science Research Work

University of California San Diego Nevada Cancer Institute
Dr. Oscar Goodman's lab, Las Vegas, NV

June. 2010 – Aug. 2010

- Worked on a basic science project "To evaluate the potential role of BRCA protein expression in determining chemotherapy sensitivities in castration-resistant metastatic prostate cancer".

- Worked on DU145 & LNCaP prostate cancer cell lines.
Work responsibilities include maintaining human cancer cell lines, expanding cell lines, plating out cells, cell extraction and protein quantification, Gel Electrophoresis, Western Blot.

Leadership/Teaching Experience

- **University of Saskatchewan, College of Medicine** June 2014 - current
Clinical Assistant Professor
Actively involved in teaching medical students and residents and nursing staff as part of preceptor ship program at University of Saskatchewan College of Medicine .
- **Michigan State University, Lansing, MI** Sep 2012 – June 2013
Clinical fellow/Instructor
Involved in resident teaching during their Hematology/Oncology rotation
- **University of Nevada School of Medicine, Las Vegas, NV** June 2012
Chief Resident Medical Oncology Fellowship Program
Responsible for organizing fellow's academic rounds, on-call scheduling of fellows and residents, and liaison for resident concerns to program committee
- **University of Nevada School of Medicine, Las Vegas, NV** July 2009 - June 2012
Extensive experience in teaching PGY-1 and PGY-2 Internal Medicine and Family Medicine residents

Clinical Case Presentations & Lectures

- **Novartis Canada Consultant Meeting on Breast & RCC Cancers** Dec 2nd, 2015
Sheraton Cavalier Saskatoon Hotel
Saskatchewan, Canada
- **Myeloma Advisory** Mar 27th, 2015
Janssen's Hematology-Myeloma Advisory Board
Calgary, Alberta.
 - Discuss the evolving VELCADE landscape and implications to physician treatment choice
 - Review and discuss novel mechanisms of action for therapies in Myeloma
 - Discuss the clinical development plan for Daratumumab and the implications of recent clinical outcomes
- **Side Effect Management and Dose Adjustments of MTOR** Nov 26, 2014
Breast CME
Regina, Saskatchewan
- **Management of CLL; A new treatment era is born** Mar 2014
Allan Blair Cancer Center, Regina, Sk, Canada
- **Maintenance/Consolidation Treatment in Multiple Myeloma** June 2013
Dept. of Hematology & Oncology, Michigan State University, Lansing MI

- **Cancer of Unknown Primary**
Dept. of Hematology & Oncology, Michigan State University, Lansing MI

May 2013
- **Management of CLL**
Dept. of Hematology & Oncology, Michigan State University, Lansing MI

Feb 2013
- **Regorafenib monotherapy for previously treated metastatic Colorectal Cancer (CORRECT TRIAL)**
Dept. of Hematology & Oncology, Michigan State University, Lansing MI

Jan 2013
- **A Case of Gelling Blood**
Research Day; University of Nevada School of Medicine, Las Vegas NV.

June 2012
- **Non Surgical Management of Stage II Non small cell lung cancer**
Dept. of Hematology & Oncology, Veterans Affairs, Las Vegas, NV .

May 2012
- **Relapse/Refractory Diffuse large B-cell lymphoma**
Dept. of Hematology & Oncology, Veterans Affairs, Las Vegas, NV.

May 2012
- **Waldenstorm's Macroglobulinemia; Case Presentation**
Dept. of Medical Oncology, UC San Diego NCI, Las Vegas, NV

April 2012
- **FOLFIRINOX versus Gemcitabine for metastatic Pancreatic Cancer**
Dept. of Medical Oncology, UC San Diego NCI, Las Vegas, NV

March 2012
- **Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib**
Dept. of Medical Oncology, UC San Diego NCI, Las Vegas, NV

Oct. 2011
- **Reduced Lung-Cancer Mortality with Low-Dose CT Screening**
Dept. of Medical Oncology, UC San Diego NCI, Las Vegas, NV

Aug. 2011
- **Antiplatelet therapy for secondary prevention of stroke; MATCH TRIAL & Review of Literature.**
Dept of IM, University of Nevada School of Medicine, Las Vegas, NV

June 2011
- **A rare cause of Thrombocytopenia; Case Presentation**
Dept. of IM, University of Nevada School of Medicine, Las Vegas, NV

May 2011
- **Cost-effectiveness of Dabigatran compared with Warfarin for stroke prevention in atrial fibrillation**
Dept. of IM University of Nevada School of Medicine, Las Vegas, NV

Feb 2011
- **Non-Atherosclerotic causes of Coronary Artery Disease**
Grand Rounds, Dept. of IM University of Nevada School of Medicine, Las Vegas, NV

Dec. 2010

- **Myocardial Bridge cause of NSTEMI, Case Presentation** Sep 2010
Cardiac Catheterization Conference,
Dept. of IM University of Nevada School of Medicine, Las Vegas, NV
- **Ahmed A, Fawaz S, Greenberg A. Rifampicin Hypersensitivity:
A Multi system Mystery** Dec 2009
American College of Physicians 2010 Nevada Chapter meeting
- **Efficacy of MRI and Mammography for Breast-Cancer
Screening in Women with a Familial or Genetic Predisposition,** June 2009
Dept.of IM. University of Nevada School of Medicine, Las Vegas, NV

Professional Affiliations/Memberships

- American College of Physicians
- American Medical Associations
- American Society of Clinical Oncology
- American Society of Hematology
- Michigan Society of Hematology and Oncology
- Saskatchewan Medical Association
- Royal College of Physicians and Surgeons of Canada Maintenance of Certification (MOC) Program
- College of physicians and Surgeons of Saskatchewan
- Alliance
- National Cancer Institute of Canada Clinical Trials Group
- NRG Oncology
- ACCRU (Academic and Community Cancer Research United)

Honors & Awards

- Doctor of Medicine/M.B.B.S ; **Second Position**
Karachi Medical & Dental College / Abbasi Shaheed Hospital, Pakistan.
- Department of Basic Science; Distinction in Anatomy
Karachi Medical & Dental College / Abbasi Shaheed Hospital, Pakistan.
- Department of Basic Science; Distinction in Physiology
Karachi Medical & Dental College / Abbasi Shaheed Hospital, Pakistan.
- Department of Community Medicine; Distinction in Community Health Sciences.
Karachi Medical & Dental College / Abbasi Shaheed Hospital, Pakistan.

Licensure

- Active Medical License
 - ☐ State of Michigan, USA
 - ☐ Saskatchewan, Canada
-